Companies /Healthcare

Arcutis Biotherapeutics Inc

NASDAQ: ARQT Biotechnology
$27.07
▼ $1.19 (−4.22%) today
Markets open · 4:04pm ET

ARQT at a Glance

Valuation
Market cap
$3.6B
P/E ratio
128.5
Profitability
Revenue (TTM)
$508.7M
Profit margin
5.9%
EPS (TTM)
$0.22
Price
52-week range
$19 – $35
Street target
$40.38

Headquartered in Westlake Village, CA Fiscal year ends December NASDAQ: ARQT arcutis.com

About Arcutis Biotherapeutics

Arcutis Biotherapeutics (Nasdaq: ARQT) is a commercial-stage medical dermatology company focused on immuno-dermatology. It develops and sells treatments for immune-mediated skin diseases.

Its commercial franchise is ZORYVE (roflumilast), a potent and selective phosphodiesterase-4 (PDE4) inhibitor taken once daily. It comes in cream (0.3%, 0.15%, 0.05%) and topical foam (0.3%) formulations. ZORYVE is approved in the United States and Canada for plaque psoriasis, atopic dermatitis and seborrheic dermatitis. The company sells it through a dermatology sales force and a newly launched primary care and pediatric sales team.

Arcutis is pursuing several label expansions for ZORYVE:
- infant atopic dermatitis for cream 0.05% (FDA target action date February 23, 2027);
- moderate to severe atopic dermatitis for cream 0.3% (Phase 3);
- vitiligo and hidradenitis suppurativa for foam 0.3% (Phase 2);
- cutaneous adverse events from checkpoint inhibitors (Phase 2 in preparation).

It is also developing ARQ-234, a CD200 receptor checkpoint agonist, in a Phase 1a/1b trial for atopic dermatitis. Revenue comes from net product sales of ZORYVE. Updated

Latest Activity

ARQTArcutis Biotherapeutics
Q3 2026
EPS
$0.06
est $0.17-64.3%
Revenue
$144M
est $143M+0.9%

Arcutis missed EPS expectations because SG&A jumped to $99.6 million from $62.4 million a year ago to fund a new primary care and pediatric sales force. Revenue still grew 45% and management raised full-year net product sales guidance to $535 million to $545 million, with an FDA decision on ZORYVE cream for infants due February 23, 2027.

Quarterly EPS — reported vs estimate

ARQT Coverage

Frequently Asked Questions

What does Arcutis Biotherapeutics do?

Arcutis Biotherapeutics (Nasdaq: ARQT) is a commercial-stage medical dermatology company focused on immuno-dermatology. It develops and sells treatments for immune-mediated skin diseases.

What is the ARQT stock price target?

The Wall Street consensus 12-month price target for ARQT is $40.38.